Certest Showcases Range of Rapid Tests and Real Time PCR Detection Kits at MEDICA 2021
|
By LabMedica International staff writers Posted on 15 Nov 2021 |
|
CerTest Biotec (Zaragoza, Spain) showcased its range of rapid tests and real time PCR detection kits at the MEDICA 2021 trade fair held in Düsseldorf, Germany from 15-18th November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.
CerTest highlighted different products for infectious diseases, tumor and inflammation markers detection. The company also presented its range of enzymes for molecular biology and qPCR. CerTest highlighted its range of monoclonal antibodies with high sensitivity and specificity by using highly stable and pure immunogens and an in-house improved screening; liquid recombinant proteins with high purity and stability, through a process of cloning, expression, multi-step purification and buffer optimization; native antigens -inactivated- comprising a wide variety of bacteria and viruses; and molecular biology enzymes with high specific activity and high stability, with and w/o glycerol that are suitable for qPCR and RT-qPCR.
CerTest also presents its rapid test diagnostic products for detecting the presence of antigens with the immunochromatographic lateral flow technique. These products included rapid diagnostic tests for gastrointestinal, respiratory infectious diseases, and the detection of inflammatory or tumor markers in the GI tract. The company demonstrated why its rapid tests are easy to use, along with its robust and stable diagnostic devices that are designed to provide the best performance in the simplest way and at the lowest associated operational costs. Also on display was CerTest’s Turbilatex product line including turbidimetric assays based on the agglutination reaction between antibody-coated latex particles and the antigen in solution, as well as reagents that permit a high-sensitivity detection method to be obtained. The intended use for Turbilatex products is to detect and quantify the antigen present in human stool samples.
Additionally, CerTest showcased its VIASURE Real Time PCR Detection Kits that are designed for the diagnosis of infectious diseases caused by different pathogens in human samples. This product range is based on 5’ nuclease chemistry. This technology utilizes two primers and a hydrolysis probe and exploits the exonuclease activity of Taq DNA polymerase. During the amplification, the increase in the fluorescent signal is proportional to the quantity of target sequence present in the sample and could be measured on a wide range of Real Time PCR platforms. VIASURE Real Time PCR Detection Kit contains in each well all the necessary components for Real Time PCR assay in a stabilized format, which allows the shipment at room temperature.
Related Links:
CerTest Biotec
Latest Medica 2021 News
- MEDICA 2021 + COMPAMED 2021 Far Exceed Expectations and Achieve Extremely Successful Results
- POC System that Requires Single DNA Molecule for Rapid Detection of Multidrug-Resistant Pathogens Unveiled at MEDICA 2021
- Icomes Lab Demonstrates World's Smallest and Lightest Electronic Pipette for PCR Testing at MEDICA 2021
- Bosch Exhibits Vivalytic All-in-One Analyzer for PCR Rapid Tests at MEDICA 2021
- Co-Diagnostics Introduces Its Revolutionary Coprimer Technology at MEDICA 2021
- MGI Tech Showcases World-First High-Throughput Automated Sample Transfer Processing System at MEDICA 2021
- Edan Debuts Next-Gen Blood Gas & Chemistry Analyzer and Patient Monitor at MEDICA 2021
- EKF Diagnostics Showcases STAT-Site WB β-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021
- Boditech Launches New Automated Immunoassay Analyzer with Blood Collection Tube at MEDICA 2021
- Molgen Presents Diagnostics Chemistry, Flows and Systems at MEDICA 2021
- Randox Showcases Extensive Range of Revolutionary Diagnostic Analyzers at MEDICA 2021
- Molbio Exhibits Its Novel POC Molecular Platform and Truenat Range of Tests at MEDICA 2021
- Greiner Bio-One Exhibits Its New Generation of Sapphire Pipette Tips at MEDICA 2021
- LumiraDx Presents Its Innovative, Next Generation Point of Care Diagnostics Platform at MEDICA 2021
- Medix Biochemica Celebrates Launch of New Molecular Diagnostic Reagents Division at MEDICA 2021
- Fujirebio Highlights Its Innovative IVD Testing Solutions for Today and Tomorrow at MEDICA 2021
Channels
Clinical Chemistry
view channel
Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
Early diagnosis of liver fibrosis remains challenging because the condition often progresses without symptoms, while traditional assessments rely on invasive biopsy or costly imaging. Timely identification... Read more
Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
Molecular Diagnostics
view channel
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Pathology
view channel
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
Colorectal cancer remains a leading cause of cancer mortality, and many patients relapse despite apparently successful surgery and chemotherapy. Detecting minimal disease that persists after treatment... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
